RESUMO
Bone loss associated with chronic inflammatory diseases has been attributed to the release of cytokines from T lymphocytes. However, the role of T lymphocyte subsets in the mediation of osteoclast activity has not been extensively studied. Cocultures of murine bone marrow and BALC cells (murine calvarial-derived cell line) were used to study osteoclast differentiation. Murine marrow was left intact or depleted of cells expressing the CD8 or CD4 antigen by immunomagnetic separation and then cocultured with BALC cells in the presence or absence of 1,25-(OH)2D3. Depleting bone marrow of CD4-positive (CD4+) cells did not affect osteoclast differentiation (formation of tartrate-resistant acid phosphatase positive cells with three or more nuclei). However, depletion of CD8-positive (CD8+) cells resulted in a 40% increase in the number of osteoclasts formed. Addition of CD8+ cells to CD8+ cell depleted cocultures via Transwells abolished the stimulatory effects on osteoclast differentiation resulting from CD8+ cell depletion. Neutralizing antibodies to interleukin-4 and transforming growth factor-beta did not affect osteoclast differentiation in these cultures. These findings suggest that CD8+ cells may be involved in the regulation of osteoclast differentiation and that this effect is not mediated by interleukin-4 or transforming growth factor-beta.
Assuntos
Linfócitos T CD8-Positivos/fisiologia , Diferenciação Celular , Osteoclastos/citologia , Animais , Células da Medula Óssea , Osso e Ossos/citologia , Linfócitos T CD4-Positivos/fisiologia , Técnicas de Cocultura , Separação Imunomagnética , Interleucina-4/análise , Interleucina-4/antagonistas & inibidores , Interleucina-4/fisiologia , Camundongos , Camundongos Endogâmicos BALB C , Fator de Crescimento Transformador beta/análise , Fator de Crescimento Transformador beta/antagonistas & inibidores , Fator de Crescimento Transformador beta/fisiologiaRESUMO
Selective estrogen receptor modulators are an emerging class of pharmaceutically important molecules. Many compounds in this class contain an aminoethoxyaryl moiety attached to a polycyclic framework at an asymmetric carbon atom. To assess whether this carbon atom can be replaced by nitrogen, we have employed a Ninomiya enamide photocyclization for the rapid synthesis of a novel N-arylbenzophenanthridine framework, 4. Further elaboration of 4 into a new structural class of achiral, nonsteroidal estrogen receptor modulators is described.
Assuntos
Fenantridinas/síntese química , Receptores de Estrogênio/efeitos dos fármacos , Animais , Antineoplásicos/síntese química , Antineoplásicos/química , Ligação Competitiva , Ciclização , Antagonistas de Estrogênios/síntese química , Antagonistas de Estrogênios/química , Antagonistas de Estrogênios/farmacologia , Humanos , Técnicas In Vitro , Fenantridinas/química , Fenantridinas/farmacologia , Fotoquímica , Ensaio Radioligante , Ratos , Receptores de Estrogênio/metabolismo , Células Tumorais CultivadasRESUMO
Raloxifene,[2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (2), is representative of a class of compounds known as selective estrogen receptor modulators (SERMs) that possess estrogen agonist-like actions on bone tissues and serum lipids while displaying potent estrogen antagonist properties in the breast and uterus. As part of ongoing SAR studies with raloxifene, we found that replacement of the carbonyl group with oxygen ([6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene hydrochloride, 4c) resulted in a substantial (10-fold) increase in estrogen antagonist potency relative to raloxifene in an in vitro estrogen dependent cell proliferation assay (IC50 = 0.05 nM) in which human breast cancer cells (MCF-7) were utilized. In vivo, 4c potently inhibited the uterine proliferative response to exogenous estrogen in immature rats following both sc and oral dosing (ED50 of 0.006 and 0.25 mg/kg, respectively). In ovariectomized aged rats, 4c produced a significant maximal decrease (45%) in total cholesterol at 1.0 mg/kg (p.o.) and showed a protective effect on bone relative to controls with maximal efficacy at 1.0 mg/kg (p.o.). These data identify 4c as a novel SERM with greater potency to antagonize estrogen in uterine tissue and in human mammary cancer cells compared to raloxifene, tamoxifen or ICI-182,780.
Assuntos
Antagonistas de Estrogênios/síntese química , Piperidinas/síntese química , Receptores de Estrogênio/agonistas , Animais , Neoplasias da Mama/patologia , Divisão Celular/efeitos dos fármacos , Antagonistas de Estrogênios/química , Antagonistas de Estrogênios/farmacologia , Feminino , Humanos , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Estrutura Molecular , Piperidinas/química , Piperidinas/farmacologia , Cloridrato de Raloxifeno , Ratos , Ratos Sprague-Dawley , Células Tumorais CultivadasRESUMO
The 2-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. A series of raloxifene analogs which contain modifications to the 2-arylbenzothiophene core have been prepared and evaluated for the ability to bind to the estrogen receptor and inhibit MCF-7 breast cancer cell proliferation in vitro. Their ability to function as tissue-selective estrogen agonists in vivo has been assayed in a short-term, ovariectomized (OVX) rat model with end points of serum cholesterol lowering, uterine weight gain, and uterine eosinophil peroxidase activity. These studies have demonstrated that (1) the 6-hydroxy and, to a lesser extent, the 4'-hydroxy substituents of raloxifene are important for receptor binding and in vitro activity, (2) small, highly electronegative 4'-substituents such as hydroxy, fluoro, and chloro are preferred both in vitro and in vivo, (3) increased steric bulk at the 4'-position leads to increased uterine stimulation in vivo, and (4) additional substitution of the 2-aryl moiety is tolerated while additional substitution at the 4-, 5-, or 7-position of the benzothiophene results in reduced biological activity. In addition, compounds in which the 2-aryl group is replaced by alkyl, cycloalkyl, and naphthyl substituents maintain a profile of in vitro and in vivo biological activity qualitatively similar to that of raloxifene. Several novel structural variants including 2-cyclohexyl, 2-naphthyl, and 6-carbomethoxy analogs also demonstrated efficacy in preventing bone loss in a chronic OVX rat model of postmenopausal osteopenia, at doses of 0.1-10 mg/kg.
Assuntos
Antagonistas de Estrogênios/síntese química , Antagonistas de Estrogênios/farmacologia , Piperidinas/síntese química , Piperidinas/farmacologia , Receptores de Estrogênio/efeitos dos fármacos , Adenocarcinoma/tratamento farmacológico , Animais , Sítios de Ligação , Osso e Ossos/efeitos dos fármacos , Neoplasias da Mama/tratamento farmacológico , Divisão Celular/efeitos dos fármacos , Colesterol/sangue , Antagonistas de Estrogênios/metabolismo , Feminino , Humanos , Masculino , Tamanho do Órgão/efeitos dos fármacos , Ovariectomia , Piperidinas/metabolismo , Cloridrato de Raloxifeno , Ratos , Ratos Sprague-Dawley , Receptores de Estrogênio/metabolismo , Relação Estrutura-Atividade , Útero/anatomia & histologia , Útero/efeitos dos fármacos , Útero/enzimologiaRESUMO
The 2-arylbenzothiophene raloxifene, 1, is a selective estrogen receptor modulator (SERM) which is currently under clinical evaluation for the prevention and treatment of postmenopausal osteoporosis. In vivo structure-activity relationships and molecular modeling studies have indicated that the orientation of the basic amine-containing side chain of 1, relative to the stilbene plane, is an important discriminating factor for the maintenance of tissue selectivity. We have constructed a series of analogues of 1 in which this side chain is held in an orientation which is orthogonal to the stilbene plane, similar to the low-energy conformation predicted for raloxifene. Herein, we report on the synthesis of these compounds and on their activity in a series of in vitro and in vivo biological assays reflective of the SERM profile. In particular, we describe their ability to (1) bind the estrogen receptor, (2) antagonize estrogen-stimulated proliferation of MCF-7 cells in vitro, (3) stimulate TGF-beta3 gene expression in cell culture, (4) inhibit the uterine effects of ethynyl estradiol in immature rats, and (5) potently reduce serum cholesterol and protect against osteopenia in ovariectomized (OVX) rats without estrogen-like stimulation of uterine tissue. These data demonstrate that one of these compounds, LY357489,4, is among the most potent SERMs described to date with in vivo efficacy on bone and cholesterol metabolism in OVX rats at doses as low as 0.01 mg/kg/d.
Assuntos
Antagonistas de Estrogênios/síntese química , Naftoquinonas/síntese química , Piperidinas/farmacologia , Receptores de Estrogênio/antagonistas & inibidores , Animais , Densidade Óssea/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Colesterol/sangue , Antagonistas de Estrogênios/química , Antagonistas de Estrogênios/farmacologia , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Células HeLa , Humanos , Modelos Moleculares , Conformação Molecular , Naftoquinonas/química , Naftoquinonas/metabolismo , Naftoquinonas/farmacologia , Tamanho do Órgão/efeitos dos fármacos , Ovariectomia , Piperidinas/química , Piperidinas/metabolismo , Cloridrato de Raloxifeno , Ratos , Ratos Sprague-Dawley , Receptores de Estrogênio/metabolismo , Relação Estrutura-Atividade , Fator de Crescimento Transformador beta/biossíntese , Fator de Crescimento Transformador beta/genética , Células Tumorais Cultivadas , Útero/efeitos dos fármacos , Útero/metabolismoRESUMO
Representative non-steroidal estrogens, from common environmental sources such as plants, pesticides, surfactants, plastics, and animal health products, demonstrated an ability to lower serum cholesterol and prevent bone loss. Specifically, select environmental estrogens (coumestrol, genistein, methoxychlor, bisphenol A, and zeranol) effectively lowered total serum cholesterol in an estrogen-dependent animal model, the ovariectomized rat. Of these entities, coumestrol, methoxychlor, and zeranol prevented ovariectomy-induced bone loss. In an in vitro environment, these compounds competed with 17beta-estradiol for estrogen receptor binding and stimulated cell proliferation in a human breast cancer cell line (MCF-7). In addition to their well-documented effects on reproductive tissue, various environmental estrogens can dramatically affect non-reproductive parameters such as cholesterol lowering and bone metabolism.
Assuntos
Anticolesterolemiantes , Densidade Óssea/efeitos dos fármacos , Colesterol/sangue , Cumestrol/farmacologia , Poluentes Ambientais/farmacologia , Estrogênios não Esteroides/farmacologia , Isoflavonas/farmacologia , Metoxicloro/farmacologia , Fenóis/farmacologia , Útero/fisiologia , Zeranol/farmacologia , Adenocarcinoma , Animais , Compostos Benzidrílicos , Ligação Competitiva , Neoplasias da Mama , Linhagem Celular , Estradiol/metabolismo , Feminino , Genisteína , Humanos , Cinética , Ovariectomia , Ratos , Ratos Sprague-Dawley , Receptores de Estrogênio/metabolismo , Útero/efeitos dos fármacosRESUMO
Raloxifene (LY139481 HCl) is a selective estrogen receptor modulator (SERM) which blocks the effects of estrogen on some tissues, such as the breast and uterus, while mimicking estrogen in other tissues, such as bone. To study the origins of this unique pharmacology, we have prepared the major metabolites of raloxifene as chemical probes for examining the estrogen receptor function in vitro and in vivo. In human breast cancer cell (MCF-7) related assays, these glucuronide conjugates show little affinity for the estrogen receptor and are more than two orders of magnitude less potent at inhibiting cell proliferation than raloxifene. In non-traditional estrogen target tissue, such as bone, these metabolites are less effective than the parent at inhibiting cytokine-stimulated bone resorbing activity in rat osteoclasts or producing transforming growth factor beta-3 (TGF-beta3). In animal models, tissue distribution studies with radiolabelled metabolite indicate that conversion to raloxifene occurs readily in a variety of tissues including the liver, lung, spleen, kidney, bone and uterus. Differential conversion of metabolite in target organs, such as bone and the uterus, is not observed indicating that the origin of raloxifene's pharmacology does not result from tissue-selective deconjugation of metabolite to parent.
Assuntos
Antagonistas de Estrogênios/metabolismo , Glucuronatos/farmacocinética , Piperidinas/metabolismo , Piperidinas/farmacocinética , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Animais , Reabsorção Óssea , Neoplasias da Mama/metabolismo , Neoplasias da Mama/patologia , Divisão Celular , Células Cultivadas , Estradiol/metabolismo , Antagonistas de Estrogênios/farmacocinética , Feminino , Glucuronatos/síntese química , Glucuronatos/metabolismo , Humanos , Interleucina-6/farmacologia , Especificidade de Órgãos , Osteoclastos/efeitos dos fármacos , Osteoclastos/fisiologia , Ovariectomia , Piperidinas/síntese química , Cloridrato de Raloxifeno , Ratos , Ratos Sprague-Dawley , Receptores de Estrogênio/agonistas , Receptores de Estrogênio/metabolismo , Distribuição Tecidual , Fator de Crescimento Transformador beta/biossíntese , Células Tumorais CultivadasAssuntos
Piperidinas/farmacologia , Receptores de Estrogênio/agonistas , Receptores de Estrogênio/antagonistas & inibidores , Animais , Densidade Óssea/efeitos dos fármacos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/metabolismo , Divisão Celular/efeitos dos fármacos , Colesterol/sangue , Etinilestradiol/farmacologia , Feminino , Humanos , Pessoa de Meia-Idade , Tamanho do Órgão/efeitos dos fármacos , Especificidade de Órgãos , Cloridrato de Raloxifeno , Ratos , Tamoxifeno/farmacologia , Células Tumorais Cultivadas , Útero/anatomia & histologia , Útero/metabolismoRESUMO
The lesion of chronic periodontitis is characterized by the persistence of perivascular collections of degenerate plasma cells. In this study, immunohistochemical demonstration of amyloid P (AP) component was used to define the distribution of this protein in established periodontitis lesions and in biopsies of non-destructive marginal gingivitis. Quantitative assessment of AP indicated significantly higher levels in periodontitis than in gingivitis for all regions of the tissue. This was associated with pathology as determined by the intensity of plasma cell accumulation and the extent of connective tissue matrix degradation. AP was concentrated in the deep connective tissue areas but perivascular accumulation was also noted, as was deposition associated with nerve bundles and, occasionally, in the extracellular matrix of the lining epithelium. These findings have potential significance in relation to the pathology of chronic periodontitis as AP has been shown to interact in a calcium-dependent manner with a number of ligands including fibronectin, elastic fibres, C-4 binding protein and amyloid fibrils.
Assuntos
Gengivite/metabolismo , Periodontite/metabolismo , Componente Amiloide P Sérico/metabolismo , Adulto , Vasos Sanguíneos/metabolismo , Vasos Sanguíneos/patologia , Proteínas de Transporte/metabolismo , Doença Crônica , Complemento C4/metabolismo , Tecido Conjuntivo/metabolismo , Tecido Conjuntivo/patologia , Tecido Elástico/metabolismo , Tecido Elástico/patologia , Epitélio/metabolismo , Epitélio/patologia , Matriz Extracelular/metabolismo , Fibronectinas/metabolismo , Gengivite/patologia , Humanos , Imuno-Histoquímica , Integrina alfaXbeta2 , Fibras Nervosas/metabolismo , Fibras Nervosas/patologia , Bolsa Periodontal/metabolismo , Bolsa Periodontal/patologia , Periodontite/patologia , Plasmócitos/patologiaRESUMO
Immunohistological studies have established an association between the deposition of the amyloid P protein and disease status in chronically inflamed periodontal tissues. The aim of this study was to determine if amyloid-like fibrils could be extracted from these tissues. Biopsies were homogenised and extracted exhaustively in saline before serial extraction in distilled water. Electrophoretic analysis revealed the presence of previously undetected protein bands in the fifth water extraction. These were probed and were found to react with antisera to kappa and lambda immunoglobulin light chains but not with antisera to mu, gamma or alpha heavy chains. Electron microscopic study indicated fibrils of 9.7 nm diameter. These bound Congo Red and exhibited green birefringence under polarised light. The results supported the presence of an amyloid-like matrix composed of immunoglobulin light chains in the lesions of chronic periodontitis. This could explain the persistence of foci of degenerate plasma cells and the paucity of granulation tissue formation in the disease process.
Assuntos
Periodontite/metabolismo , Componente Amiloide P Sérico/análise , Amiloide/análise , Biópsia , Doença Crônica , Vermelho Congo , Eletroforese em Gel de Poliacrilamida , Matriz Extracelular/metabolismo , Matriz Extracelular/ultraestrutura , Imunofluorescência , Tecido de Granulação/patologia , Humanos , Imunoglobulina A/análise , Imunoglobulina G/análise , Cadeias Leves de Imunoglobulina/análise , Imunoglobulina M/análise , Cadeias kappa de Imunoglobulina/análise , Cadeias lambda de Imunoglobulina/análise , Microscopia Eletrônica , Periodontite/patologia , Plasmócitos/patologiaRESUMO
To extend and confirm previous data, we examined the effects of raloxifene on the proximal tibia of ovariectomized rats, aged 6 months, longitudinally and cross-sectionally by computed tomography (pQCT) and then compared the effects to those of orally dosed estrogen. Comparative analysis of phantoms and rat bones showed that the pQCT is precise and correlates with a Hologic QDR 1000W (DXA) with R = 0.999 but is capable of measuring significant differences between groups when the DXA cannot. This may reflect the ability of the pQCT to determine bone volume, mineral content (mg) and volumetric mineral density (mg/cm3), compared with two-dimensional analyses performed with DXA. Longitudinal analysis of the proximal tibia in vivo showed a significant 17% reduction in mineral density 31 days after ovariectomy. Examination of the images from ovariectomized rats showed a progressive increase in the cross-sectional area of the proximal tibiae, loss of trabecular bone, widening of marrow spaces and thinning of the cortical bone wall opposite the fibula. Regression analysis of the dose-dependent protective effects of raloxifene showed the half-maximal efficacy on tibiae mineral density to be ED50 = 0.4 mg/kg/day per os by pQCT and 0.2 mg/kg/day by DXA. By comparison, 17 alpha ethynyl estradiol showed dose-dependent effects with ED50 = 0.013 mg/kg/day per os by pQCT. Both raloxifene and ethynyl estradiol had beneficial effects on serum lipids, producing 50% reduction of cholesterol at 0.1 mg/kg/day raloxifene and 80% reduction with 0.01 mg/kg/day ethynyl estradiol. However, raloxifene up to 10 mg/kg/day had little effect on uterine weight, whereas 0.01 mg/kg/day ethynyl estradiol increased uterine wet weight by 300%.(ABSTRACT TRUNCATED AT 250 WORDS)